Back to All NewsInterim Phase 1 results reported for investigational oral HOPO-101

Interim Phase 1 results reported for investigational oral HOPO-101

Interim results from the first-in-human Phase 1 clinical trial of investigational HOPO-101 (NCT05628961) were reported by SRI International at the fall meeting of the Radiation Research Society. In 42 healthy participants receiving single oral doses of up to 7,500 mg, HOPO-101 was generally well-tolerated, with no serious adverse events or dose-limiting toxicities reported. Pharmacokinetic data showed dose-proportional exposure with rapid absorption and clearance within 24 hours, consistent with nonclinical experience. These results mark an important step in the continued development of HOPO-101 as a potential orally-administered treatment for individuals with known or suspected internal radionuclide contamination. The study has been funded by the National Institute of Allergy and Infectious Diseases.